Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00066274
- Locations
- 🇫🇷
Centre Regional Francois Baclesse, Caen, France
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00065117
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00040820
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Prologue Research International
- Registration Number
- NCT00062426
- Locations
- 🇺🇸
Physicians East - Quadrangle, Greenville, North Carolina, United States
🇺🇸Northwestern Connecticut Oncology-Hematology Associates, Torrington, Connecticut, United States
🇺🇸Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 102
- Registration Number
- NCT00061815
- Locations
- 🇺🇸
ImClone Investigational Site, Richmond, Virginia, United States
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-14
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2472
- Registration Number
- NCT00004931
- Locations
- 🇺🇸
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, United States
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 35
- Registration Number
- NCT00004127
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00060411
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00059930
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
- Conditions
- First Posted Date
- 2003-05-05
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005837
- Locations
- 🇺🇸
CCOP - Columbia River Program, Portland, Oregon, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.